Innate ImmunityNCT03637894
Immunity Modification of Full Term Infants According to the Type of Feeding and Mode of Delivery
A study testing Feeding infants with fermented formula milk, Feeding infants with standard formula milk and Breastfeeding infants in people with Innate Immunity and Newborns, run by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico at 1 site in Italy.
Trial summary
This is a single-center, double-blind, randomized controlled trial, with parallel groups and reference group. The aim of the study was to investigate whether feed a fermented formula milk leads to an increase of anti-microbial peptides such as catelecidine, alpha and beta defensins and secretory-IgA, compared to feed… Read more about this study
- Who is it for?
- Ages 1 day to 7 daysHealthy volunteers can take part
- Conditions the study is for
- Innate Immunity, Newborns, Nutrition
- What is being tested?
- Feeding infants with fermented formula milk, Feeding infants with standard formula milk and Breastfeeding infants
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 96 participants
- Where
- 1 siteItaly
- Study dates
- 26 Aug 2015to 21 Jun 2017
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 day to 7 days
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- Full term healthy infants
- Gestational age from 37 to 41 weeks
- Weight appropriate for gestational age (from 10th to 90th centile according to World Health Organization chart)
- Human milk not available or not possible
Who cannot join
- Weight small for gestational age (< 10th centile) or large for gestational age (> 90th centile) according to World Health Organization chart
- Congenital abnormalities, chromosomal, hearth, gastrointestinal, respiratory, neurological or metabolic disease.
- Perinatal infections
- Positive familiarity for milk proteins allergies
Trial locations and contacts
1 site in 1 country.
About this study
This is a single-center, double-blind, randomized controlled trial, with parallel groups and reference group. The aim of the study was to investigate whether feed a fermented formula milk leads to an increase of anti-microbial peptides such as catelecidine, alpha and beta defensins and secretory-IgA, compared to feed a standard formula (Plasmon Primigiorni), according to mode of delivery. Breastfed infants were the reference group.
Read the detailed description
The microbiota plays an important role in modulating the development of the immune system, making decisive the interrelation that between nutrition, microbiota and immune cells to modulate long-term health outcomes.
The type of feeding, especially breastfeeding, and the type of delivery are factors that can contribute to the development of the microbiota. Specifically, the exclusive breastfeeding promotes the development of bifidobacteria that promotes protection against potential infections and the development of the immune system.
In recent years it was improved the biological effects of formula milk, that represent the substitutes of breast milk when this is not available or if there are contraindications to breastfeeding. Functional foods derived from fermentation of cow's milk with probiotic strains have been proposed for the prevention of infectious diseases of the child. Recently, in a monocentric double-blind prospective study, the efficacy of fermented cow's milk with Lactobacillus paracasei CBA L74 was evaluated in the prevention of common winter infections in children aged between 12 and 48 months. In this study, children treated with fermented milk had a lower incidence of respiratory and gastrointestinal tract infections compared to the control group. This effect was associated with a significant stimulation of innate immunity (α- and β-defensin, LL-37) and acquired (secretory IgA) and to a modulation of composition and function of the intestinal microbiota characterized by a significant increase in strains producing butyric acid (Firmicutes phyla). The nutritional intervention was very well accepted by the children and no adverse events were observed.
Primary objectives of this study were:
To evaluate whether the feeding with a fermented formulated milk determines an increase in anti-microbial peptides such as catelecidine, alpha and beta defensin and secretory IgA compared to the feed with the standard formula (Plasmon Primigiorni), with reference to the mother's milk.
Secondary objective:
- Value the tolerance in the two groups of infants fed with the two formulas in the study, with reference to the group of infants fed with breast milk.
- Value the modifications of the intestinal microbiota in the two groups of infants fed with the two formulas in the study, with reference to the group of infants fed with breast milk.
Study design: Single-center, randomized, double-blind, parallel group study with reference group.
Methods:
- Evaluation of the anthropometric parameters (weight, length and cranial circumference)
- Evaluation of body composition by plethysmography
- Evaluation of the gastrointestinal tolerance of fermented formulated milk by means of data collection and diary delivery to the parents of the participants
- Evaluation of the safety of fermented formulated milk by recording adverse events
- Determination of faecal samples of antimicrobial peptides (defensins, catelecidines), IgA, microbiota and metabolome.
Infants will be enrolled at birth (within 7 days of life) upon acquisition of the informed consent of both parents.
At the time of enrollment, newborns who take breast milk due to the absence of breast milk will be randomized to receive up to the third month of age or a fermented formulated milk or a standard formula (Plasmon First Days).
Enrollment will be carried out by promoting and supporting breastfeeding and, in the event of exclusive breastfeeding forecasts for at least the first 3 months of age, newborns will be included in the study as a control group.
There are 3 medical visits to enrollment (V0), the first (V1) and the third month of life (V2).
During the visits the anthropometric parameters, the body composition, and the gastroenteric tolerance will be evaluated. A stool sample will also be collected at the three points of the life study in order to determine the anti-microbial peptides (catelecidine, alpha and beta defensin) and the secretory IgA, and perform the analysis of the microbiota and the metabolome.
Statistical analysis:
The sample size was determined to identify between the two groups of infants, the one that received the fermented formulated milk and the one that received standard formulated milk (Plasmon Primigiorni), a difference in the content of faecal α-defensins on samples of feces. Considering the results of the effect of a treatment with milk fermented with L. paracasei CBA L74 on fecal α-defensins in children attending preschool centers mean value (DS) vs placebo [4.8 (4.2) vs 1 (0.6), respectively] we calculated that 12 newborns are needed per group with a power of 84% and an alpha of 0.05. Assuming a 30% drop-out rate, at least 16 newborns per group must be recruited.
Criteria for the evaluation of variables The descriptive analyzes will be performed by calculating mean, median and standard deviations for the continuous variables and expressing the distribution of the frequencies for the discrete variables. The main analysis will resort to tests for independent samples, Student or Mann-Whitney tests according to the distribution of the outcome variables. To jointly analyze the trend in time from V0 to V2 of the outcome variables in the two groups, the one that received the fermented formulated milk and the one that received the standard formula, based on the type of delivery (spontaneous or cesarean) will be used regression models for repeated measurements (random effects models or GEE models).
- Conditions
- Innate Immunity, Newborns, Nutrition, Microbiota
- Being tested
- Feeding infants with fermented formula milk, Feeding infants with standard formula milk, Breastfeeding infants
- Keywords
- Newborns, Fermented milk, Innate immunity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Feeding infants with fermented formula milkDietary supplement
Infants enrolled were fed either with fermented formula milk or with standard formula during the first four months of life. Breastfed infants were the reference group.
Feeding infants with standard formula milkOther
Infants enrolled were fed either with fermented formula milk or with standard formula during the first four months of life. Breastfed infants were the reference group.
Breastfeeding infantsOther
Reference group
| Study group | Role | What they receive |
|---|---|---|
| Infants born by CS-fed fermented formula | Active comparator | Feeding infants with fermented formula milk. Infants born by cesarean section were fed either with fermented formula milk or with standard formula during the first 3 months of life Receives: Dietary Supplement: Feeding infants with fermented formula milk |
| Infants born by CS-fed standard formula | Placebo comparator | Feeding infants with standard formula milk. Infants born by cesarean section were fed either with fermented formula milk or with standard formula during the first 3 months of life Receives: Other: Feeding infants with standard formula milk |
| Infants born by CS-breastfed | Other | Infants born by cesarean section fed with mother milk during were the reference group for all infants born by cesarean section.
The breastfeeding infants were the reference group Receives: Other: Breastfeeding infants |
| Infants born by ED-fed fermented formula | Active comparator | Feeding infants with fermented formula milk. Infants born by eutocic delivery were fed either with fermented formula milk or with standard formula during the first 3 months of life Receives: Dietary Supplement: Feeding infants with fermented formula milk |
| Infants born by ED-fed standard formula | Placebo comparator | Feeding infants with standard formula milk. Infants born by eutocic delivery were fed either with fermented formula milk or with standard formula during the first 3 months of life Receives: Other: Feeding infants with standard formula milk |
| Infants born by ED-breastfed | Other | Infants born by eutocic delivery were fed either with fermented formula milk or with standard formula during the first 3 months of life.
The breastfeeding infants were the reference group. Receives: Other: Breastfeeding infants |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from baseline Innate immunity at 30 days of life and at 90 days of life.
Fecal dosage of catelecidines, alfa and beta defensins and sIgA
Measured: 0-7 days of life, at 30 days of life and at 90 days of life.
Secondary outcomes (6)
Gastrointestinal tolerance
Gastrointestinal tolerance was evaluated by the use of a daily diary computed by the parents to record vomiting/gaseous colics/stool frequency.
Measured: 0-7 days of life, at 30 days of life and at 90 days of life.
Weight
weight (g)
Measured: 0-7 days of life, at 30 days of life and at 90 days of life.
Body composition
Body composition assessment in term of fat mass and fat free mass by air displacement
Measured: 0-7 days of life and at 90 days of life.
Anthropometry
length and head circumference (cm)
Measured: 0-7 days of life, at 30 days of life and at 90 days of life.
Microbiota
gut microbiota assessment
Measured: 0-7 days of life and at 90 days of life.
Metabolomics
stool metabolomic analysis
Measured: 0-7 days of life and at 90 days of life.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Aug 2018
- Study start26 Aug 2015
- Primary completion21 Jun 2017
- Study completion21 Jun 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Innate ImmunityStudies of the same condition, open and under way.
- More trials run by Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- RCT double blind study
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 96 participants (actual)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Collaborators
- Heinz Italia SpA
- Responsible party
- Sponsor
- Investigators
- Fabio Mosca, Prof, Principal investigator, NICU. Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milano, Milan, Italy, 20122
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03637894
- Sponsor's protocol ID
- FERT15
- Status last verified
- Jan 2018
- First submitted
- 11 Jan 2018
- Last updated
- 20 Aug 2018
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: The individual participant data will not shared with other researchers.
Publications
Nocerino R, Paparo L, Terrin G, Pezzella V, Amoroso A, Cosenza L, Cecere G, De Marco G, Micillo M, Albano F, Nugnes R, Ferri P, Ciccarelli G, Giaccio G, Spadaro R, Maddalena Y, Berni Canani F, Berni Canani R. Cow's milk and rice fermented with Lactobacillus paracasei CBA L74 prevent infectious diseases in children: A randomized controlled trial. Clin Nutr. 2017 Feb;36(1):118-125. doi: 10.1016/j.clnu.2015.12.004. Epub 2015 Dec 17.
PubMed 26732025Zagato E, Mileti E, Massimiliano L, Fasano F, Budelli A, Penna G, Rescigno M. Lactobacillus paracasei CBA L74 metabolic products and fermented milk for infant formula have anti-inflammatory activity on dendritic cells in vitro and protective effects against colitis and an enteric pathogen in vivo. PLoS One. 2014 Feb 10;9(2):e87615. doi: 10.1371/journal.pone.0087615. eCollection 2014.
PubMed 24520333Thibault H, Aubert-Jacquin C, Goulet O. Effects of long-term consumption of a fermented infant formula (with Bifidobacterium breve c50 and Streptococcus thermophilus 065) on acute diarrhea in healthy infants. J Pediatr Gastroenterol Nutr. 2004 Aug;39(2):147-52. doi: 10.1097/00005176-200408000-00004.
PubMed 15269618Indrio F, Ladisa G, Mautone A, Montagna O. Effect of a fermented formula on thymus size and stool pH in healthy term infants. Pediatr Res. 2007 Jul;62(1):98-100. doi: 10.1203/pdr.0b013e31806772d3.
PubMed 17515847Roggero P, Liotto N, Pozzi C, Braga D, Troisi J, Menis C, Gianni ML, Berni Canani R, Paparo L, Nocerino R, Budelli A, Mosca F, Rescigno M. Analysis of immune, microbiota and metabolome maturation in infants in a clinical trial of Lactobacillus paracasei CBA L74-fermented formula. Nat Commun. 2020 Jun 1;11(1):2703. doi: 10.1038/s41467-020-16582-1.
PubMed 32483147
Study at a glance
From the registry record, last updated by the sponsor on 20 Aug 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Immunity Modification of Full Term Infants According to the Type of Feeding and Mode of Delivery
- ClinicalTrials.gov ID
- NCT03637894
- Acronym / sponsor ID
- FERT15
- Conditions
- Innate Immunity, Newborns, Nutrition, Microbiota
- Keywords
- Newborns, Fermented milk, Innate immunity
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 96 participants (actual)
- Lead sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoUniversity, hospital or other
- Collaborators
- Heinz Italia SpA
- Study start
- 26 Aug 2015 (actual)
- Primary completion
- 21 Jun 2017 (actual)
- Study completion
- 21 Jun 2017 (actual)
- First posted
- 20 Aug 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a single-center, double-blind, randomized controlled trial, with parallel groups and reference group. The aim of the study was to investigate whether feed a fermented formula milk leads to an increase of anti-microbial peptides such as catelecidine, alpha and beta defensins and secretory-IgA, compared to feed a standard formula (Plasmon Primigiorni), according to mode of delivery. Breastfed infants were the reference group.
Detailed description
The microbiota plays an important role in modulating the development of the immune system, making decisive the interrelation that between nutrition, microbiota and immune cells to modulate long-term health outcomes.
The type of feeding, especially breastfeeding, and the type of delivery are factors that can contribute to the development of the microbiota. Specifically, the exclusive breastfeeding promotes the development of bifidobacteria that promotes protection against potential infections and the development of the immune system.
In recent years it was improved the biological effects of formula milk, that represent the substitutes of breast milk when this is not available or if there are contraindications to breastfeeding. Functional foods derived from fermentation of cow's milk with probiotic strains have been proposed for the prevention of infectious diseases of the child. Recently, in a monocentric double-blind prospective study, the efficacy of fermented cow's milk with Lactobacillus paracasei CBA L74 was evaluated in the prevention of common winter infections in children aged between 12 and 48 months. In this study, children treated with fermented milk had a lower incidence of respiratory and gastrointestinal tract infections compared to the control group. This effect was associated with a significant stimulation of innate immunity (α- and β-defensin, LL-37) and acquired (secretory IgA) and to a modulation of composition and function of the intestinal microbiota characterized by a significant increase in strains producing butyric acid (Firmicutes phyla). The nutritional intervention was very well accepted by the children and no adverse events were observed.
Primary objectives of this study were:
To evaluate whether the feeding with a fermented formulated milk determines an increase in anti-microbial peptides such as catelecidine, alpha and beta defensin and secretory IgA compared to the feed with the standard formula (Plasmon Primigiorni), with reference to the mother's milk.
Secondary objective:
- Value the tolerance in the two groups of infants fed with the two formulas in the study, with reference to the group of infants fed with breast milk.
- Value the modifications of the intestinal microbiota in the two groups of infants fed with the two formulas in the study, with reference to the group of infants fed with breast milk.
Study design: Single-center, randomized, double-blind, parallel group study with reference group.
Methods:
- Evaluation of the anthropometric parameters (weight, length and cranial circumference)
- Evaluation of body composition by plethysmography
- Evaluation of the gastrointestinal tolerance of fermented formulated milk by means of data collection and diary delivery to the parents of the participants
- Evaluation of the safety of fermented formulated milk by recording adverse events
- Determination of faecal samples of antimicrobial peptides (defensins, catelecidines), IgA, microbiota and metabolome.
Infants will be enrolled at birth (within 7 days of life) upon acquisition of the informed consent of both parents.
At the time of enrollment, newborns who take breast milk due to the absence of breast milk will be randomized to receive up to the third month of age or a fermented formulated milk or a standard formula (Plasmon First Days).
Enrollment will be carried out by promoting and supporting breastfeeding and, in the event of exclusive breastfeeding forecasts for at least the first 3 months of age, newborns will be included in the study as a control group.
There are 3 medical visits to enrollment (V0), the first (V1) and the third month of life (V2).
During the visits the anthropometric parameters, the body composition, and the gastroenteric tolerance will be evaluated. A stool sample will also be collected at the three points of the life study in order to determine the anti-microbial peptides (catelecidine, alpha and beta defensin) and the secretory IgA, and perform the analysis of the microbiota and the metabolome.
Statistical analysis:
The sample size was determined to identify between the two groups of infants, the one that received the fermented formulated milk and the one that received standard formulated milk (Plasmon Primigiorni), a difference in the content of faecal α-defensins on samples of feces. Considering the results of the effect of a treatment with milk fermented with L. paracasei CBA L74 on fecal α-defensins in children attending preschool centers mean value (DS) vs placebo [4.8 (4.2) vs 1 (0.6), respectively] we calculated that 12 newborns are needed per group with a power of 84% and an alpha of 0.05. Assuming a 30% drop-out rate, at least 16 newborns per group must be recruited.
Criteria for the evaluation of variables The descriptive analyzes will be performed by calculating mean, median and standard deviations for the continuous variables and expressing the distribution of the frequencies for the discrete variables. The main analysis will resort to tests for independent samples, Student or Mann-Whitney tests according to the distribution of the outcome variables. To jointly analyze the trend in time from V0 to V2 of the outcome variables in the two groups, the one that received the fermented formulated milk and the one that received the standard formula, based on the type of delivery (spontaneous or cesarean) will be used regression models for repeated measurements (random effects models or GEE models).
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 6
- Model description
- RCT double blind study
| Arm | Type | Receives |
|---|---|---|
| Infants born by CS-fed fermented formula | Active comparator | Dietary Supplement: Feeding infants with fermented formula milkFeeding infants with fermented formula milk. Infants born by cesarean section were fed either with fermented formula milk or with standard formula during the first 3 months of life |
| Infants born by CS-fed standard formula | Placebo comparator | Other: Feeding infants with standard formula milkFeeding infants with standard formula milk. Infants born by cesarean section were fed either with fermented formula milk or with standard formula during the first 3 months of life |
| Infants born by CS-breastfed | Other | Other: Breastfeeding infantsInfants born by cesarean section fed with mother milk during were the reference group for all infants born by cesarean section. The breastfeeding infants were the reference group |
| Infants born by ED-fed fermented formula | Active comparator | Dietary Supplement: Feeding infants with fermented formula milkFeeding infants with fermented formula milk. Infants born by eutocic delivery were fed either with fermented formula milk or with standard formula during the first 3 months of life |
| Infants born by ED-fed standard formula | Placebo comparator | Other: Feeding infants with standard formula milkFeeding infants with standard formula milk. Infants born by eutocic delivery were fed either with fermented formula milk or with standard formula during the first 3 months of life |
| Infants born by ED-breastfed | Other | Other: Breastfeeding infantsInfants born by eutocic delivery were fed either with fermented formula milk or with standard formula during the first 3 months of life. The breastfeeding infants were the reference group. |
Who may qualify
- Ages
- 1 day to 7 days
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Key inclusion criteria (4 listed)
- Full term healthy infants
- Gestational age from 37 to 41 weeks
- Weight appropriate for gestational age (from 10th to 90th centile according to World Health Organization chart)
- Human milk not available or not possible
Key exclusion criteria (4 listed)
- Weight small for gestational age (< 10th centile) or large for gestational age (> 90th centile) according to World Health Organization chart
- Congenital abnormalities, chromosomal, hearth, gastrointestinal, respiratory, neurological or metabolic disease.
- Perinatal infections
- Positive familiarity for milk proteins allergies
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Feeding infants with fermented formula milkInfants enrolled were fed either with fermented formula milk or with standard formula during the first four months of life. Breastfed infants were the reference group. | Dietary supplement | Infants born by CS-fed fermented formula, Infants born by ED-fed fermented formula |
| Feeding infants with standard formula milkInfants enrolled were fed either with fermented formula milk or with standard formula during the first four months of life. Breastfed infants were the reference group. | Other | Infants born by CS-fed standard formula, Infants born by ED-fed standard formula |
| Breastfeeding infantsReference group | Other | Infants born by CS-breastfed, Infants born by ED-breastfed |
Primary outcome
Change from baseline Innate immunity at 30 days of life and at 90 days of life.
Time frame: 0-7 days of life, at 30 days of life and at 90 days of life.
Fecal dosage of catelecidines, alfa and beta defensins and sIgA
6 secondary outcomes
Gastrointestinal tolerance
Time frame: 0-7 days of life, at 30 days of life and at 90 days of life.
Weight
Time frame: 0-7 days of life, at 30 days of life and at 90 days of life.
Body composition
Time frame: 0-7 days of life and at 90 days of life.
Anthropometry
Time frame: 0-7 days of life, at 30 days of life and at 90 days of life.
Microbiota
Time frame: 0-7 days of life and at 90 days of life.
Metabolomics
Time frame: 0-7 days of life and at 90 days of life.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Aug 2018.
- Results publication: PubMed 26732025Nocerino R, Paparo L, Terrin G, Pezzella V, Amoroso A, Cosenza L, Cecere G, De Marco G, Micillo M, Albano F, Nugnes R, Ferri P, Ciccarelli G, Giaccio G, Spadaro R, Maddalena Y, Berni Canani F, Berni Canani R. Cow's milk and rice fermented with Lactobacillus paracasei CBA L74 prevent infectious diseases in children: A randomized controlled trial. Clin Nutr. 2017 Feb;36(1):118-125. doi: 10.1016/j.clnu.2015.12.004. Epub 2015 Dec 17.
- Results publication: PubMed 24520333Zagato E, Mileti E, Massimiliano L, Fasano F, Budelli A, Penna G, Rescigno M. Lactobacillus paracasei CBA L74 metabolic products and fermented milk for infant formula have anti-inflammatory activity on dendritic cells in vitro and protective effects against colitis and an enteric pathogen in vivo. PLoS One. 2014 Feb 10;9(2):e87615. doi: 10.1371/journal.pone.0087615. eCollection 2014.
- Results publication: PubMed 15269618Thibault H, Aubert-Jacquin C, Goulet O. Effects of long-term consumption of a fermented infant formula (with Bifidobacterium breve c50 and Streptococcus thermophilus 065) on acute diarrhea in healthy infants. J Pediatr Gastroenterol Nutr. 2004 Aug;39(2):147-52. doi: 10.1097/00005176-200408000-00004.
- Results publication: PubMed 17515847Indrio F, Ladisa G, Mautone A, Montagna O. Effect of a fermented formula on thymus size and stool pH in healthy term infants. Pediatr Res. 2007 Jul;62(1):98-100. doi: 10.1203/pdr.0b013e31806772d3.
- Derived from this study: PubMed 32483147Roggero P, Liotto N, Pozzi C, Braga D, Troisi J, Menis C, Gianni ML, Berni Canani R, Paparo L, Nocerino R, Budelli A, Mosca F, Rescigno M. Analysis of immune, microbiota and metabolome maturation in infants in a clinical trial of Lactobacillus paracasei CBA L74-fermented formula. Nat Commun. 2020 Jun 1;11(1):2703. doi: 10.1038/s41467-020-16582-1.
- Individual participant dataSharing planned: No. The individual participant data will not shared with other researchers.
Related trials for Innate Immunity
Recruiting
Lung Immune Challenge Study: Controlled Exposure to Inhaled Resiquimod (R848)
Innate Immunity, Mucosal Immunity
Enrolling by invitationObservational study
Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders
Primary Immunodeficiency, DOCK8
RecruitingObservational study
Study of the Effect of Innate on the Inflammatory Response to Endotoxin
Asthma, Atherosclerosis
RecruitingObservational study
Send-In Sample Collection for Comprehensive Analyses of Innate and Adaptive Immune Responses During Acute COVID-19 and Convalescence
COVID-19 Infection
Not yet recruiting
Effect of Aronia Supplementation on the LPS-CD14-TLR2/4 Axis in Football Players
Exercise Training
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Fabio Mosca, Prof principal investigator
NICU. Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milano, Milan, Italy, 20122
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Feeding infants with fermented formula milk, Feeding infants with standard formula milk and Breastfeeding infants in people with Innate Immunity and Newborns, run by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Aug 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from baseline Innate immunity at 30 days of life and at 90 days of life. (time frame: 0-7 days of life, at 30 days of life and at 90 days of life.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03637894, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Aug 2018.